Compare Keysight Technologies Inc (KEYS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs TransMedics Group Inc — how do they compare? Keysight Technologies Inc trades at $382.98 (market cap $63.79B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Keysight Technologies Inc is far larger — about 23.3× TransMedics Group Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and TransMedics Group Inc for 24 Days on average.
| KEYS | TMDX | |
|---|---|---|
Market Cap | $63.79B | $2.74B |
Volume | 1,435,384 | 949,331 |
Sector | Technology | Health |
52-Week High | $387.90 | $150.42 |
52-Week Low | $159.49 | $61.99 |
Typical Hold Time | 56 Days | 24 Days |
Enterprise Value | $63.93B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.61, up 0.29% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with accelerating earnings, beating estimates for three consecutive quarters, and impressive profitability metrics including 19.14% net income margin and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, positioning the company for continued growth.
KEYS presents a compelling investment case with strong analyst consensus (81% buy ratings) and a $416.63 price target offering 8.9% upside. However, elevated valuation ratios (P/E 50.7, P/S 9.85) and supply chain constraints present near-term risks. The company's leadership in AI testing and 6G technology provides long-term growth catalysts despite current premium pricing.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
